Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Birelentinib in Diffuse Large B-Cell Lymphoma: NCT07059650 Clinical Landscape Report 2026
28 September 2026
NCT07059650 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Imipramine Hydrochloride in Recurrent Glioma: NCT07074756 Clinical Landscape Report 2026
28 September 2026
NCT07074756 clinical landscape for Recurrent Glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Neoplasm Metastasis: NCT07046923 Clinical Landscape Report 2026
28 September 2026
NCT07046923 clinical landscape for Neoplasm Metastasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pegfilgrastim (Amgen) in Ovarian Cancer: NCT07064018 Clinical Landscape Report 2026
28 September 2026
NCT07064018 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
68Ga/64Cu-FAPI-XT117 in Glioblastoma: NCT07067905 Clinical Landscape Report 2026
28 September 2026
NCT07067905 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anbalcabtagene autoleucel in Refractory Central Nervous System Lymphoma: NCT07062627 Clinical Landscape Report 2026
28 September 2026
NCT07062627 clinical landscape for Refractory Central Nervous System Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Ferumoxytol in Diffuse Large B-Cell Lymphoma: NCT07066436 Clinical Landscape Report 2026
28 September 2026
NCT07066436 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Datopotamab Deruxtecan in Residual Neoplasm: NCT07069595 Clinical Landscape Report 2026
28 September 2026
NCT07069595 clinical landscape for Residual Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pidnarulex in High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: NCT07069699 Clinical Landscape Report 2026
28 September 2026
NCT07069699 clinical landscape for High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: endpoints, sponsor, phase, geography, readouts, a…
9 min read
Carboplatin in Recurrent Triple-Negative Breast Carcinoma: CTRI/2025/07/091252 Clinical Landscape Report 2026
28 September 2026
CTRI/2025/07/091252 clinical landscape for Recurrent Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and deve…
9 min read
Orelabrutinib in Diffuse Large B-Cell Lymphoma: NCT07078500 Clinical Landscape Report 2026
28 September 2026
NCT07078500 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sargramostim in PD-L1 negative Triple Negative Breast Cancer: NCT07078604 Clinical Landscape Report 2026
28 September 2026
NCT07078604 clinical landscape for PD-L1 negative Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…